関連する実験動画

Updated: Jul 15, 2026

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
08:42

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

Published on: January 15, 2018

抗ウイルス遺伝子の誘導性に対する染色体21の用量効果 (s)

U H Tan

    Nature
    |January 24, 1975
    PubMed
    まとめ

    No abstract available in PubMed .

    さらに関連する動画

    Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
    15:49

    Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

    Published on: June 9, 2022

    Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
    08:32

    Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

    Published on: May 23, 2025

    関連する実験動画

    Last Updated: Jul 15, 2026

    Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
    08:42

    Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

    Published on: January 15, 2018

    Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
    15:49

    Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

    Published on: June 9, 2022

    Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
    08:32

    Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

    Published on: May 23, 2025

    関連する概念動画

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    JoVEについて
    概要リーダーシップブログJoVEヘルプセンター
    著者向け
    出版プロセス編集委員会範囲と方針査読よくある質問投稿
    図書館員向け
    推薦の声購読アクセスリソース図書館諮問委員会よくある質問
    研究
    JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
    教育
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
    利用規約
    プライバシーポリシー
    ポリシー
    Jove
    Visualize
    お問い合わせ